Verona Pharma Stock Quote VRNA - Stock Price, News, Charts, Message Board, Trades

Register for real-time alerts, custom portfolio, and market movers

Get Started

Home
Investing
Stocks
USA
NASDAQ
Verona Pharma Plc (VRNA) Quote

Verona Pharma Plc (VRNA)

29.40

0.17

(0.58%)

Closed September 19 4:00PM

Delayed by 15 minutes

29.50

0.10

( 0.34% )

Pre Market: 4:02AM

Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Current Price

29.50

Bid

25.00

Ask

29.50

Volume

103

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

Previous Close

29.40

Open

-

Last Trade

Last Trade Time

04:01:29

Financial Volume

-

VWAP

-

Average Volume (3m)

-

Shares Outstanding

81,235,156

Dividend Yield

-

PE Ratio

0.00

Earnings Per Share (EPS)

-

Revenue

-

Net Profit

-54.37M

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which ... Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.veronapharma.com

Headquarters

London, Gbr

Founded

-

Verona Pharma Plc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VRNA. The last closing price for Verona Pharma was $29.40. Over the last year, Verona Pharma shares have traded in a share price range of $ 0.00 to $ 0.00.

Verona Pharma currently has 81,235,156 shares outstanding. The market capitalization of Verona Pharma is $2.39 billion.

Overall Flow

Bullish

Net Premium

161k

Calls / Puts

100.00%

Buys / Sells

50.00%

OTM / ITM

50.00%

Sweeps Ratio

0.00%

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST...

Form 4 - Statement of changes in beneficial ownership of securities

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview...

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BNZIBanzai International Inc	$ 7.20 (150.00%)	949.99k
GDHGGolden Heaven Group Holdings Ltd	$ 5.57 (80.84%)	158.69k
LFLYLeafly Holdings Inc	$ 3.10 (73.18%)	2.51M
TNONTenon Medical Inc	$ 7.49 (48.91%)	2.04M
SVMHSRIVARU Holding Ltd	$ 0.1795 (44.76%)	20.77M
KRKR36Kr Holdings Inc	$ 0.15 (-25.00%)	28
TOMZTOMI Environmental Solutions Inc	$ 0.585 (-23.03%)	1.04k
NCINeo Concept International Group Holdings Ltd	$ 0.6913 (-17.70%)	62.24k
CUTRCutera Inc	$ 0.65 (-15.60%)	1
OMEXOdyssey Marine Exploration Inc	$ 0.9694 (-15.34%)	584.67k
SVMHSRIVARU Holding Ltd	$ 0.1795 (44.76%)	20.77M
RRRichtech Robotics Inc	$ 1.065 (15.45%)	5.64M
LFLYLeafly Holdings Inc	$ 3.10 (73.18%)	2.51M
TNONTenon Medical Inc	$ 7.49 (48.91%)	2.04M
NDRAENDRA Life Sciences Inc	$ 0.2043 (-3.31%)	1.7M

Hoskuld

Hoskuld 7 days ago

That is great GB!

gbrown6332

gbrown6332 1 week ago

Saw your original post on VRNA. Sounded good. Decided to tag along. Glad I did.

Thks,

G. Brown

powerwalker

powerwalker 4 weeks ago

Someone certainly does not want this stock to go and stay above $28.

Hoskuld

Hoskuld 1 month ago

Got it - you meant pharmacies not pharmas (which are drug manufacturing companies.) Makes sense. I will actually check to see if ohtuvayre is at local CVS this week!

I can imagine you would be excited about this and I am really looking forward to hearing about your experience with it! Thanks for sharing!

Roger1

Roger1 1 month ago

Btw, I didn't say it wasn't going well. I said it takes time for any new drug given the logistics. I think they're doing a great job or i wouldn't have invested in them.

Roger1

Roger1 1 month ago

Checked out the drug with CVS and was told about specialty pharmas. I'm a COPD patient and respiratory therapist and have followed trials for quite a while and am delighted to try this drug. Was told the same thing by Verona when I signed up for the drug through the patient portal. I used to teach the mechanism of action of bronchodilators. Specifically C3-5AMP . Taught therapists, nurses, and many of the older physicians sat in for refresher.
Check with your pharmacist and see if it's available. I'd be interested in your findings.

Hoskuld

Hoskuld 1 month ago

They were already detailing 100 of the top 2,500 pulmonologists as of 2 weeks ago, and presumably are detailing ~20-25 more each week. The launch is already going well.

What did you mean by "speciality pharmas until then"?

Roger1

Roger1 1 month ago

I think it will be January b4 the roll out is complete. Specialty pharmas until then. Have patience, this drug will be a blockbuster with its double mechanism of action.

Hoskuld

Hoskuld 1 month ago

Hi PW - the company has said that they are looking to partner ohtuvayre in the EU and, as a part of that partnership, the partner would be responsible for developing an inhaler for ohtuvayre, too.

I agree that the company management seems sharp. And all newly launched products have issues - let's hope Verona is on top of the issues. I wrote IR and simply asked that they send me a note saying that my message was received and the responsible people at Verona are "on it".

powerwalker

powerwalker 1 month ago

Hoskuld, I listened to the quarterly cc and the Canaccord Genuity presentation and I came away with the impression that Verona management is on top of all matters: marketing, sales, and distribution. If there were a problem, it might be the pharmacies listing Ohtuvayre in their systems, given it is a new product and it needs to establish an ordering pattern for it.

Hoping the patient numbers are higher within a year.

Have you seen or heard any info on EMA and/or UK filings/approval?

Hoskuld

Hoskuld 1 month ago

Just following up on this...I can see ohtuvayre being the SOC. I think this will grow very, very swiftly.

🎯 1 👍️ 1

Hoskuld

Hoskuld 1 month ago

A couple of pulmonologists on stocktwits describe issues with scripts that they have written being fulfilled. On the other hand, one of the pulmonologists is writing 5-6 scripts per day and the other seemed to be writing 2 per day. 5-6 per day = 1,000+ per year for one high-prescribing pulmonologist. And ~400 for a less aggressive prescriber. To me, those seem like promising numbers and point to hitting 60,000+ plus patients over the next year as being probable and NOT a stretch.

🎯 1 👍️ 1

Hoskuld

Hoskuld 1 month ago

Luckily, we know the story here.

powerwalker

powerwalker 1 month ago

Not actually a "Hit" piece, but leaves negative impressions, anyway. Released earlier in late July ... must not have had the intended effect, so it tries again.

Top 3 Health Care Stocks That May Crash In August

https://www.benzinga.com/news/24/08/40365322/top-3-health-care-stocks-that-may-crash-in-august

Hoskuld

Hoskuld 1 month ago

Glad you are making money here k9uwa! I think we will see this go much higher over the next couple of years. Would really like to get access to script data...

k9uwa

k9uwa 1 month ago

Hope everyone is buckled in and enjoying the ride. I Am Wishing I had put another zero onto my purchase on this one.
Thanks U and Guzzie
John k9uwa

Hoskuld

Hoskuld 1 month ago

Anyone have IMS / IQVIA script data access for Ohtuvayre? Has been a few weeks and this is doing exactly what it should do. Hope everyone is buckled in and enjoying the ride.

Golden Cross

Golden Cross 3 months ago

$VRNA COPD drug approved
- 1st-in-class neb PDE4 inhibitor
- antinflamm + b-dilator
- Clean, broad label, no restrictions
- Complements ICS LABA LAMA, doesn't compete
- Targets broad COPD population vs. narrow biologics like Dupixent
- Big Pharma (Boehringer, GSK) easy bolt-on addition to pipeline

Golden Cross

Golden Cross 3 months ago

$VRNA NEWS FDA Approval ~ Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
$VRNA NEWS FDA Approval ~ Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)https://t.co/6gOmzKSwx2— 💸 Golden Cross Stocks 💸 (@CrossStocks) June 26, 2024

🍀 1 👍️ 1 💎 1 💯 1

HMB2010

HMB2010 3 months ago

In 2021, Nuance Pharma entered into an agreement with Verona Pharma for the exclusive rights to develop and commercialize ensifentrine in Greater China. On April 6th 2023, Nuance Pharma announced first patient in (FPI) for the ENHANCE-China Phase III clinical trial.

https://finance.yahoo.com/news/nuance-pharmas-partner-verona-pharma-090700900.html

Should be good return here!

stock1ace1

stock1ace1 3 months ago

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine

👍️ 2 💯 1 💲 1 🛫 1

Golden Cross

Golden Cross 3 months ago

so is the price already figured in or what here

🍀 1 👍️ 1 💎 1

Golden Cross

Golden Cross 3 months ago

$VRNA awaits FDA decision on June 26 for ensifentrine, a groundbreaking COPD therapy. With $901.89M in cash, they’re set for a strong future. Approval could make ensifentrine the first new inhaled #COPD treatment in 20+ years!

🍀 1 👍️ 2 💎 1 💯 1

PonkenPlonken

PonkenPlonken 4 months ago

Today, we have entered into two strategic financing agreements with Oaktree and OMERS, providing access to up to $650M to support the potential US launch of #ensifentrine and the expansion of its clinical activities.
Read more here: https://t.co/vF5GOXjXtN$VRNA pic.twitter.com/pRMLsHPe0t— Verona Pharma (@VeronaPharma) May 9, 2024
this does not look like Ensifentrine is expected to fail.

Amatuer17

Amatuer17 1 year ago

https://seekingalpha.com/article/4594258-verona-pharma-ensifentrine-vs-dupixent-ensifentrine-is-a-breath-of-fresh-air

Firstly, in the Phase 3 ENHANCE-1 and ENHANCE-2 trials, ensifentrine reported a 36% and 42% pbo-adjusted reduction in COPD exacerbation at week 24, respectively. In contrast, dupixent demonstrated a 30% pbo-adjusted reduction in COPD exacerbation at week 52 in the BOREAS trial.

Verona Pharma is expected to submit an NDA by 1H 2023, PDUFA by 1H 2024, and launch in the US by 2H 2024.

4Godnwv

4Godnwv 2 years ago

Great news today AH - this little pharm might be going places.

TheFinalCD

TheFinalCD 2 years ago

Amatuer17

Amatuer17 2 years ago

COPD is a crowded place - not sure about what is special about their drug?

Unless this drug is better than other COPD drugs - this co is fully priced @ $2 B

This co cannot market the product even if approved - so it needs to be bought out but it will not get more than $3 B - so maybe 50% premium from here

Laster

Laster 2 years ago

Very few sure bets on Nasdaq.
But I think it is a safe bet that this company will be bought out in 2023. Significantly high stock price.
Patience will pay off here.
JMO.

TheFinalCD

TheFinalCD 2 years ago

Zadie420

Zadie420 2 years ago

Which one does not have debt? Really!!!!!!

$5.8 Mil is peanuts compare to other companies. Next time read before you posted.

BottomBounce

BottomBounce 2 years ago

$VRNA Has $5.83M DEBT

TheFinalCD

TheFinalCD 2 years ago

TheFinalCD

TheFinalCD 2 years ago

https://finviz.com/quote.ashx?t=VRNA&p=d

TheFinalCD

TheFinalCD 2 years ago

NEWS https://finance.yahoo.com/news/verona-pharma-announces-ensifentrine-meets-070000223.html

crudeoil24

crudeoil24 2 years ago

Verona Pharma Announces Proposed Underwritten Public Offering Of 10M ADSs
4:42 pm ET August 9, 2022 (Benzinga) Print
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares ("ADSs"), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share (the "Offering"). All ADSs in the Offering will be offered by Verona Pharma. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.

tw0122

tw0122 2 years ago

Big COPD runner today broke 52 week highs premarket

georgie18

georgie18 3 years ago

VRNA...$6.91...Looking for a strong bouncer on the Gap Fill...imo...we shall see...

Chart...https://schrts.co/SknAkrda ...

georgie18

georgie18 3 years ago

VRNA...$7.32...on the Gappa...Psar flipped Bullish yesterday...Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company)
Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties
Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China...https://www.otcmarkets.com/stock/VRNA/news/story?e&id=1919123 ...Should be a great trader today...imo...we shall see...:partying_face:

ClayTrader

ClayTrader 4 years ago

* * $VRNA Video Chart 07-17-2020 * *

Link to Video - click here to watch the technical chart video

Pyramid2

Pyramid2 4 years ago

Congrats to all that Traded this one today!

Dubster watching

Dubster watching 4 years ago

I’ve move up!
I keep finding these pops

FAGIxDILUTIONxDDMASTER

FAGIxDILUTIONxDDMASTER 4 years ago

This thing is moving back to $6 and has a huge potential runway, even analysts are saying $34-$50 a share - I always cut their projections in half especially wedbush (who held 70,000 shares as of march 31st).

That still leaves us with a 5x potential over medium to long term - this thing can dance with news buckle up.

Clemdane

Clemdane 5 years ago

Something's brewing here

PatiencePaysOff79

PatiencePaysOff79 5 years ago

$VRNA-Someone’s got $150k on the bid at $5.80 a/ha. Something brewing again?

Polebarn

Polebarn 5 years ago

This thing at $60 yet?

BAHAHAHAHA....

BoilerRoom

BoilerRoom 5 years ago

Stop the bleed! Company is obviously diluting shares!!!

BoilerRoom

BoilerRoom 5 years ago

Calling $3.80 the bottom here.

BoilerRoom

BoilerRoom 5 years ago

How we doing here today? Green?

TheFinalCD

TheFinalCD 5 years ago

Delayed Upgrade Clock